Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in May 2025.
- Notable investors include Biominas Brasil, BiotechTown.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Celluris
- ·The full record, as it builds
Funding rounds
No funding rounds for Celluris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celluris
Developer of CAR-T immunotherapy therapy intended to treat cancer patients. The company utilizes chimeric antigen receptor T cell (CAR-T) based therapy for the treatment of different hematological and solid tumors, enabling healthcare providers to improve the results in the treatment of hematological and solid tumors.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Founded
- 2016
- Employees
- 4
- Website
- celluris.com/en/home
- Ownership
- Privately Held (backing)
Celluris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celluris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celluris in its N-PORT filings yet. We sweep new filings monthly.